Page 166 - Genentech News Today

The first genome-wide significant study of the epigenetics of age-related macular degeneration (AMD) has yielded a trove of genetic mechanisms and pathways that are responsible for this disease, a leading cause of severe vision loss in older adults. AMD results from damage in the macula, which provides clear, straight-ahead vision, and therefore is critical to the ability to read, drive and recognize faces.

Most of the top 10 pharmaceutical companies and many large biotech companies today get a portion of their preclinical/clinical research, drug...

PSG speakers present findings of the report at AXS23 and explain some of the notable results.

The Seattle-based immune sequencing firm booked $37.6 million in revenues, with 43 percent from immune medicine and 57 percent from its minimal residual disease business.

An allogeneic retinal pigment epithelial cell therapy may help slow disease progression in geographic atrophy secondary to age-related macular degeneration, according to a press release from Lineage Cell Therapeutics.

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.

Verana Health® - a digital health company elevating quality in real-world data (RWD)— will announce the development of Qdata®...

The recent FDA approval of sarilumab for the treatment of refractory polymyalgia rheumatica may have a significant and lasting impact on the use of long-term steroids for that condition.

Cytiva considers how RNA therapeutics will impact genomic medicine and cell and gene therapies.